Cantor Fitzgerald’s Abivax ABVX Stock Holding History

Cantor Fitzgerald’s Portfolio ABVX Stock Details ABVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-35,000	Closed	-$2.97M	–	212
2025 Q3	$2.97M	Buy	+35,000	New	+$2.15M	0.03%	134

Other funds holding ABVX

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Cantor Fitzgerald's ABVX Position: Q4 2025 in Review

Cantor Fitzgerald sold out of Abivax (ABVX) in Q4 2025, closing a stake of 35,000 shares — an estimated $2.97M sold.

Cantor Fitzgerald first reported a position in ABVX in Q3 2025 and held it in 1 quarter. The position peaked at $2.97M in Q3 2025. 247 funds tracked by Wall St. Rank hold ABVX as of Q4 2025.

Cantor Fitzgerald reported no remaining Abivax position as of Q4 2025 after selling out during the quarter.
Cantor Fitzgerald sold 35,000 Abivax shares in Q4 2025, an estimated $2.97M.
Cantor Fitzgerald first reported a position in Abivax in Q3 2025 and held it in 1 quarter.
Cantor Fitzgerald's Abivax position peaked at $2.97M in Q3 2025.
247 funds tracked by Wall St. Rank held Abivax as of Q4 2025.

Based on Cantor Fitzgerald's 13F filing for Q4 2025, filed 17 Feb 2026.